Market Overview

UPDATE: Morgan Stanley Downgrades Sagent Pharmaceuticals to Equal-Weight

Related SGNT
The Market In 5 Minutes: Rates Remain Unchanged, But Hikes Still Loom
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg Per 100mL Due to the Discovery of an Out of Specification Impurity

Morgan Stanley cut its rating on Sagent Pharmaceuticals (NASDAQ: SGNT) from Overweight to Equal-weight and suspended its previous price target of $27 as it sees the company's path to growth to be challenging and delayed.

Morgan Stanley said, "Downgrading to Equal-weight as the path to sustained revenue growth and margin expansion is proving longer and more challenging than we expected and key competitive and supply chain risks are materializing. That said, we continue to see long-term value in Sagent's business model. … Pricing pressure from larger competitors (oncology pricing cuts and GPO awards at the low end of expectations), the ephemeral nature of favorable FDA shortage product share and pricing, and the slow pace of FDA approvals are magnified by a concentrated revenue/profit base."

Sagent Pharmaceuticals closed at $13.21 on Friday.

Latest Ratings for SGNT

Jun 2016JefferiesMaintainsHold
Jan 2016Deutsche BankMaintainsBuy
Jan 2016JP MorganInitiates Coverage onNeutral

View More Analyst Ratings for SGNT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (SGNT)

View Comments and Join the Discussion!